Core Points - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose important information during the class period from May 7, 2025, to August 5, 2025 [1] - Allegations include that LifeMD's competitive position was overstated, and that the company did not properly account for rising customer acquisition costs, particularly in its RexMD segment and for obesity treatment drugs [1] - The deadline for shareholders to register for the class action and seek lead plaintiff status is October 27, 2025 [2] Company Specifics - LifeMD, Inc. is facing allegations of materially false and misleading statements regarding its business operations and prospects, which may have led to an artificial inflation of its stock price [1] - The lawsuit highlights concerns over the company's guidance for 2025, which was deemed reckless given the unaccounted rising customer acquisition costs [1] Legal Context - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3] - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case [2]

Core Insights - LifeMD, Inc. will report its financial results for the three and nine months ended September 30, 2025, on November 6, 2025, after the U.S. financial markets close [1] - A conference call will be held on the same day at 4:30 p.m. Eastern time to discuss the results [2] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine, laboratory and pharmacy access, and specialized treatment for over 200 conditions [3] - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, and a state-of-the-art compounding pharmacy to enhance access to high-quality and affordable care [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during a specified class period [1][3]. Summary by Sections Class Period and Allegations - The class period for the lawsuit is from May 7, 2025, to August 5, 2025 [3]. - Allegations include that LifeMD's management overstated the company's competitive position and raised 2025 guidance without properly accounting for rising customer acquisition costs, particularly in the RexMD segment and for obesity treatment drugs like Wegovy and Zepbound [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by October 25, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Insights - LifeMD, Inc. has appointed Dr. Tara Scott as ambassador and clinical advisor for its women's health program, focusing on areas such as perimenopause, menopause, hormonal balance, and long-term wellness [1][3][6] Company Commitment - The appointment of Dr. Scott reflects LifeMD's dedication to creating a comprehensive women's health offering, addressing underdiagnosed and underserved medical aspects [3][4] Program Features - LifeMD's virtual women's health program includes: - Virtual consultations combining clinical expertise, personalized therapies, and lifestyle strategies for long-term health [5] - A holistic approach with tiered subscriptions, including lab access, mail-order prescriptions, and dietitian support [5] - LifeMD+ membership providing 24/7 urgent and primary care access, prescription renewals, and a marketplace of wellness products [5] Dr. Scott's Expertise - Dr. Scott is a board-certified obstetrician/gynecologist and menopause specialist with over 25 years of experience, recognized for her research-backed hormonal balancing strategies [6][7] Market Opportunity - Women's health, particularly menopause and osteoporosis, remains underserved, with only 25% of women seeking treatment for menopause-related symptoms and over two-thirds of osteoporosis cases undiagnosed [7] - The projected market opportunity for menopause and osteoporosis is estimated to be $60-70 billion by 2030, significantly larger than current market size [7]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought LifeMD securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 27, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding LifeMD's competitive position and financial guidance, particularly concerning customer acquisition costs in the RexMD segment and obesity treatment drugs [5]. - It is claimed that the defendants' statements about LifeMD's business operations and prospects were misleading and lacked a reasonable basis, leading to investor damages when the truth was revealed [5].

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming October 27, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired LifeMD, Inc. ("LifeMD†or the "Company†) (NASDAQ: LFMD) securities between May 7, 2025 and August 5, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO LOST MONEY ON LIFEMD, INC. (LFMD), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAW. ...

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading statements regarding its financial health and growth prospects, particularly following a significant stock price decline after its earnings report in August 2025 [1][4]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, especially on May 6, 2025, when it reported first-quarter results and raised its full-year revenue and adjusted EBITDA guidance [2]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [2][3]. Financial Performance and Stock Impact - LifeMD's stock price fell over 44% the day after the company announced its second-quarter results on August 5, 2025, which missed revenue and earnings per share estimates and included a reduction in full-year guidance [4]. - During the earnings call, management attributed the poor performance to "temporary elevated customer acquisition costs" in the RexMD business and issues with patient refunds in its weight management offerings [4]. Investor Actions - Investors who suffered losses during the specified period are encouraged to participate in the lawsuit as a means to recover damages [5]. - Hagens Berman, the law firm leading the investigation, is looking into whether LifeMD was aware of but failed to disclose key operational problems [6].

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether LifeMD and certain of its officers ...

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its competitive position and financial guidance during the Class Period from May 7, 2025, to August 5, 2025 [3][7]. Allegation Details - The lawsuit claims that defendants overstated LifeMD's competitive position [3]. - It is alleged that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [3]. - The lawsuit asserts that the statements made by the defendants about LifeMD's business, operations, and prospects were materially false and misleading [3]. Next Steps - Investors who purchased LifeMD shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 27, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina and handles cases in state and federal courts across the country [5].

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that defendants materially overstated LifeMD's competitive position [2]. - It is alleged that defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [2]. - As a result, the statements made by defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].